A research program that's paying cash to people who inject drugs is raising concerns for some residents and business owners.
Gilead (GILD) announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infection, ...
Despite a mission to become a dominant cancer drug player, Gilead Sciences has as of late been locked in on its ...
The BRAAVE2020 study investigated the efficacy of switching Black Americans living with HIV to a B/F/TAF single-pill regimen.
Nov 6 (Reuters) - Gilead Sciences (GILD.O), opens new tab reported third-quarter financial ... charge related to its 2020 ...
Canalevia®-CA1 is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs to receive any type of approval from the FDABy ...
As interest in long-acting HIV prevention surges, the first few months of experience with cabotegravir in sub-Saharan Africa ...
an anesthesiologist at New York University Langone Health, tells Inverse. “That is something people worry about all the time.” Perhaps understanding how these drugs work and in what contexts ...
the lead author of a new study that looked at health records of 17 million privately insured Americans with obesity. It found that between 2022 and 2023, as prescriptions for GLP-1 drugs more than ...
HUB’s commercial lines segment accounts for nearly 50% of its total revenue. In his new position, DeSett will work closely with the company’s executive team, business segments, and resource ...
as chief commercial officer (CCO) with expanded global responsibilities. In his new role, Muglia will oversee marketing, communication, trade marketing, sales and onboard revenues, with the goal of ...
In May 2023, pharmaceutical company Eli Lilly & Company (Lilly) released the positive initial results of a clinical trial into a new Alzheimer’s drug, donanemab ... Attract even greater commercial ...